Literature DB >> 20483753

The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex.

John S Bridgeman1, Robert E Hawkins, Steve Bagley, Morgan Blaylock, Mark Holland, David E Gilham.   

Abstract

Chimeric Ag receptors (CARs) expressed in T cells permit the redirected lysis of tumor cells in an MHC-unrestricted manner. In the Jurkat T cell model system, expression of a carcinoembryonic Ag-specific CD3zeta CAR (MFEzeta) resulted in an increased sensitivity of the transduced Jurkat cell to generate cytokines when stimulated through the endogenous TCR complex. This effect was driven through two key characteristics of the MFEzeta CAR: 1) receptor dimerization and 2) the interaction of the CAR with the endogenous TCR complex. Mutations of the CAR transmembrane domain that abrogated these interactions resulted in a reduced functional capacity of the MFEzeta CAR to respond to carcinoembryonic Ag protein Ag. Taken together, these results indicate that CARs containing the CD3zeta transmembrane domain can form a complex with the endogenous TCR that may be beneficial for optimal T cell activation. This observation has potential implications for the future design of CARs for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20483753     DOI: 10.4049/jimmunol.0901766

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  82 in total

Review 1.  Smart CARs engineered for cancer immunotherapy.

Authors:  Saul J Priceman; Stephen J Forman; Christine E Brown
Journal:  Curr Opin Oncol       Date:  2015-11       Impact factor: 3.645

2.  A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

Authors:  Hiroki Torikai; Andreas Reik; Pei-Qi Liu; Yuanyue Zhou; Ling Zhang; Sourindra Maiti; Helen Huls; Jeffrey C Miller; Partow Kebriaei; Brian Rabinovich; Brian Rabinovitch; Dean A Lee; Richard E Champlin; Chiara Bonini; Luigi Naldini; Edward J Rebar; Philip D Gregory; Michael C Holmes; Laurence J N Cooper
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

Review 3.  Recent advances and discoveries in the mechanisms and functions of CAR T cells.

Authors:  Rebecca C Larson; Marcela V Maus
Journal:  Nat Rev Cancer       Date:  2021-01-22       Impact factor: 60.716

4.  CAR-T cells and combination therapies: What's next in the immunotherapy revolution?

Authors:  Maria C Ramello; Eric B Haura; Daniel Abate-Daga
Journal:  Pharmacol Res       Date:  2017-12-01       Impact factor: 7.658

Review 5.  Challenges and opportunities of allogeneic donor-derived CAR T cells.

Authors:  Yinmeng Yang; Elad Jacoby; Terry J Fry
Journal:  Curr Opin Hematol       Date:  2015-11       Impact factor: 3.284

6.  TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance.

Authors:  Yinmeng Yang; M Eric Kohler; Christopher D Chien; Christopher T Sauter; Elad Jacoby; Chunhua Yan; Ying Hu; Kelsey Wanhainen; Haiying Qin; Terry J Fry
Journal:  Sci Transl Med       Date:  2017-11-22       Impact factor: 17.956

Review 7.  CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?

Authors:  Brooke L Prinzing; Stephen M Gottschalk; Giedre Krenciute
Journal:  Expert Rev Anticancer Ther       Date:  2018-03-16       Impact factor: 4.512

Review 8.  Hematopoietic stem cells for cancer immunotherapy.

Authors:  Eric Gschweng; Satiro De Oliveira; Donald B Kohn
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 10.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.